Free Oncology CME

Includes eleven online, self-learning activities:

• The state of prostate cancer treatment: advances in approach for advanced disease –  (1 hr CE) ACCME ACPE MOC
• Ongoing challenges and optimal approaches in the management of metastatic colorectal cancer (mCRC) – (1 hr CE) ACCME ACPE MOC
• Advanced systemic mastocytosis: from recognition to treatment (Tsewang Tashi MD) – (1 hr CE) ACCME ACPE MOC
• Pancreatic Cancer: Updates from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting – (0.75 hr CE) ACCME ACPE MOC
• Metastatic urothelial carcinoma (mUC): Updates from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (Waddah Arafat MD) – (0.75 hr CE) ACCME ACPE MOC
• Taking the next step in the management of relapsed or refractory follicular lymphoma (Eric Tam MD) – (1 hr CE) ACCME ACPE MOC
• Initial- and later-line treatment considerations in advanced renal cell carcinoma (RCC) – (1 hr CE) ACCME ACPE MOC
• Treatment considerations in relapsed or refractory chronic lymphocytic leukemia (R/R CLL): evolving approaches to an evolving disease landscape – (1 hr CE) ACCME ACPE MOC
• Contemporary treatment approaches in the management of chronic graft-versus-host disease (GVHD) – (1 hr CE) ACCME ACPE MOC
• Hitting management strategies of metastatic nasopharyngeal carcinoma on the nose – (1 hr CE) ACCME ACPE MOC
• Advanced hepatocellular carcinoma (HCC) including updates from the European Society for Medical Oncology (ESMO) 2023 – (0.75 hr CE) ACCME ACPE MOC

Target Audience: HCPs including: medical oncologists, oncology surgeons, and pathologists; physicians assistants, nurse practitioners, and pharmacists specializing in oncology, hematology, gastroenterology, urology, with some overlap in otolaryngology, transplant medicine, allergy/immunology, nephrology, and hepatology

Activity Description / Statement of Need:
In this online, self-learning activity:

Systemic mastocytosis (SM) is a heterogeneous group of disorders caused by proliferation of abnormal clonal mastocytes, which accumulate in the skin and/or other organ systems. Mastocytosis, including SM, was reclassified as a distinct disease subtype in 2016, when the World Health Organization (WHO) removed mastocytosis from the myeloproliferative neoplasm (MPN) group. The WHO defines 5 SM subtypes, ranging from indolent SM, which is associated with mild symptoms and near-normal life expectancy, to mast cell leukemia, which is an aggressive hematologic malignancy associated with median survival of less than 1 year.

Target Audience:
HCPs including: hematology/oncology specialists, allergists, and clinical immunologists, dermatologists; physician assistants, nurse practitioners, and pharmacists who practice in those areas of specialty; and any other healthcare professionals with an interest in or who may clinically encounter patients with systemic mastocytosis.

Over 64,000 people develop and close 50,000 die each year of pancreatic cancer, and by 2030, pancreatic cancer is expected to surpass colorectal and breast cancer to become the second-leading cause of cancer death. Over 90% of whom have pancreatic ductal adenocarcinoma (PDAC), and while the 5-year survival rate for patients diagnosed with localized disease is over 44%, patients with locally advanced (LAPC) or metastatic disease have a median overall survival of 12 to 14 months. Symptoms associated with pancreatic cancer are not usually evident in the early stages of the disease and may be intermittent and nonspecific, and more than half of patients have advanced disease by the time they are diagnosed.

Each year, more than 290,000 cases of breast cancer are diagnosed, making it the leading cause of cancer among females in the United States. Although earlier screening and more effective treatment options have improved outcomes among people with breast cancer, more than 43,000 people die from this type of cancer each year. Throughout the course of breast cancer management, bone health remains an important consideration. In early breast cancer, chemotherapy-induced ovarian failure and endocrine therapy can contribute to BMD loss and subsequent osteoporosis and fracture. In advanced breast cancer, about 70% of all patients will experience bone metastases, placing patients at risk for SREs. In fact, breast cancer is associated with the highest risk of SREs among all tumor types.

Maintaining bone health in patients with breast cancer requires routine monitoring and proactive management to minimize the risk of BMD loss, osteoporosis, and SREs. Guidelines therefore recommend that patients with non-metastatic breast cancer initiating aromatase inhibitors or other treatment that causes bone loss undergo dual-energy X-ray absorptiometry (DXA) scans to assess baseline BMD. Furthermore, patients at risk for osteoporosis should receive regular follow-up DXA scans to monitor for BMD loss. This represents an opportunity for ongoing education about the need for monitoring to ensure maintenance of optimal bone health.

In this online, self-learning activity:

Multiple myeloma (MM) is the most common hematologic malignancy after non-Hodgkin lymphoma, with an incidence of over 34,000 and an annual mortality rate of over 12,000. MM-induced osteocyte apoptosis facilitates MM cell survival, and patients with MM are at high risk for bone disease. Osteolytic lesions are reported in up to four out of five newly diagnosed with MM, and throughout their disease course, up to 90% of patients will eventually develop bone lesions. The presence of bone lesions increases MM patient risk for skeletal-related events (SREs), such as fractures, spinal cord compression, or need for surgery or radiotherapy. Bone disease and SREs can have serious consequences in MM, leading to worsened quality-of-life and prospects for survival. Patients who experience fracture after MM diagnosis have a two-fold increased risk of death relative to those who do not experience fracture. Yet bone disease frequently goes untreated in patients with MM, suggesting that clinicians are not familiar with the serious effects of MM.

Activity Description / Statement of Need:

In this online, self-learning activity:

Graft-versus-host disease (GvHD) is an immune-mediated response that occurs in recipients of allogenic hematopoietic cell transplantation (HCT). GvHD can be further categorized into acute and chronic cases. Maculopapular rash, follicular erythema, epidermolysis, are common manifestations of acute GvHD, in addition to liver and gastrointestinal dysfunction such as hyperbilirubinemia, nausea, and diarrhea. This activity focuses on chronic GvHD, which has more extensive multi-organ involvement including the liver, eyes, mouth, lungs, skin, genitalia, and gastrointestinal tract.

Target Audience:

The following HCPs: hematologists and oncologists; nurse practitioners, physician assistants, and pharmacists who specialize in oncology; and those who otherwise commonly care for or clinically encounter patients with GVHD.